Investors and Partners

Q-Sera’s technology is based on intellectual property from The University of Queensland (UQ) Centre for Clinical Research, which was identified and developed by UniQuest, the main commercialization company of The University of Queensland.

 

Q-Sera has the support of leading Australian Investors, Uniseed and the Medical Research Commercialization Fund (MRCF).

About UniQuest

UniQuest is the commercialisation company of The University of Queensland (UQ).  In partnership with UQ researchers, we create impact through the commercialisation of UQ intellectual property (IP). Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia.  UniQuest has formed more than 100 start-up companies built on UQ IP. These companies have raised more than A$850 million to advance UQ technologies towards the market and have created more than 230 new jobs.   UniQuest’s track record and notable successes include the blockbuster cervical cancer vaccine Gardasil® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-up exits in Australian history. Marketed products containing UQ IP licensed by UniQuest have generated gross sales of more than A$40 billion, significantly contributing to societal and economic impact. UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI), a world-class small molecule drug discovery and development group, dedicated to translating academic biomedical research into drug candidates for partnering. For more information, visit www.uniquest.com.au.

 

About Uniseed

Uniseed is Australia’s longest-running venture fund, operating at the Universities of Melbourne, Queensland, Sydney & New South Wales, and the CSIRO, with investment capital provided by these research organisations and investment partners. Uniseed is a mutual fund, owned by research organisations, for research organisations. These research organisations collectively spend $4 billion on research annually, making up over 40% of the total research spend in all research organisations in Australia. The fund facilitates the commercialisation of its research partners’ most promising intellectual property and secures targeted investment in resulting products and technologies.  Uniseed has supported 60 start-up companies, being the seed investor in most of these, and has exited ten investments, to date. For more information, visit www.uniseed.com

 

About Brandon Capital Partners and the Medical Research Commercialisation Fund (MRCF)

Brandon Capital Partners is Australasia’s leading life science venture capital investor with more than $800 million under management. As manager of the Medical Research Commercialisation Fund (MRCF), we work with scientists, clinicians and entrepreneurs from company formation and seed investment through to expansion capital, supporting life science companies from proof-of-concept through to commercialisation. The MRCF is a unique collaboration between major Australian pension funds, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals. The MRCF supports the development and commercialisation of early-stage biomedical discoveries associated with member organisations, providing both capital and expertise to guide the successful development of new therapies. The MRCF has supported more than 50 start-up companies to date, most of which were founded by the MRCF.

For more information about the MRCF visit: https://www.mrcf.com.au/

For more information about Brandon Capital Partners visit: www.brandoncapital.com.au

Supported by the Australian Government through Accelerating Commercialisation, an element of the Entrepreneur’s Programme.